Description
Pembrolizumab is a humanized PD-1 monoclonal antibody used for cancer immunotherapy. It currently has the most approved indications, as well as it is used in more tumors’ treatments than other drugs are. China approved Pembrolizumab’s first indication in China in 2018, and approved for five more until 2020, including melanoma; single-agent or combined chemotherapy for first-line treatment with positive PD-L1 expression and no EGFR or ALK mutations locally advanced or metastatic non-small cell lung cancer; PD-L1 tumor proportion score (TPS) ≥ 1% EGFR gene mutation (negative) and ALK (negative) first-line monotherapy for locally advanced or metastatic non-small cell lung cancer; first-line treatment for locally advanced or metastatic non-small-cell lung cancer (NSCLC); second-line treatment for esophageal cancer; and first-line monotherapy for head squamous cell carcinoma (HNSCC).
According to CRI market research, after Pembrolizumab entered the Chinese market, its sales revenue has increased several times. The revenue in 2020 reaches approximately CNY 294.75 million, and the CAGR is 284.67% from 2018 to 2020. Thus, CRI analyzes that the market size of Pembrolizumab will expand in the future due to the increased numbers of approved indications.
In addition, PD-1-type drug is not very common in the Chinese market, so Merck Sharp & Dohme Corp, as the only supplier of Pembrolizumab in China, did not face any threat in the past. However, in December 2018, a PD-1 drug produced by Junshi Biosciences has been successfully approved for marketing. Therefore, CRI predicts that from 2021 to 2025, the price of Pembrolizumab in China may be lowered, but the market will continue to expand due to Pembrolizumab’s effectiveness and unsaturated demand.
Topics Covered:
-The impact of COVID-19 on China’s pembrolizumab market
– Sales value and volume of China’s pembrolizumab 2016-2020
– Competitive landscape of China’s pembrolizumab market
– Prices of pembrolizumab in China
– Prices of pembrolizumab in China by regions and manufacturers
– Analysis on factors affecting the development of China’s pembrolizumab market
– Prospect of China’s pembrolizumab market from 2021 to 2025
